Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
504studies shown
Showing 326-350 of 504
CompletedNCT01983904

DBS for Treatment Resistant Depression

This study exists to see whether cognitive behavioural therapy, a structured talking treatment, can play a useful role in care. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.

DepressionOtherFrom 20 Years to 70 Years
Countries
Canada
Sponsor
University of Calgary
Condition
Depression
CompletedNCT02989727

Melancholic Symptoms in Depression in bipolarity and Responsiveness to Lamotrigine

This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve sleep, daily rhythms, and longer-term stability.

DepressionOtherOver 18 Years
Countries
Canada
Sponsor
University of Saskatchewan
Condition
Depression
TerminatedNCT02355366

Family Focused Therapy for Teens at Risk for Bipolarity

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand what a therapy or guided support program could change in day-to-day care and decision-making.

BipolarityOtherFrom 13 Years to 19 Years
Countries
Canada
Sponsor
Sunnybrook Health Sciences Centre
Condition
Bipolarity
CompletedNCT02121106

Remote Cognitive Remediation

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Canada
Sponsor
Queen's University
Condition
Schizophrenia
CompletedNCT00254488

Treatment of Bipolar Mania in Older Adults

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand whether a medication treatment can better prevent setbacks and support longer-term stability.

BipolarityOtherOver 60 Years
Countries
Canada, United States
Sponsor
Weill Medical College of Cornell University
Condition
Bipolarity
CompletedNCT01710709

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolarity I

This study exists to compare options and see whether the medication OPC-14597 offers something meaningfully different. Researchers are trying to understand whether the medication OPC-14597 can give earlier or clearer feedback during care.

BipolarityOtherFrom 18 Years to 65 Years
Countries
Canada, France, Hungary, Japan, Malaysia, Poland, Romania, South Korea, Taiwan, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity
TerminatedNCT01121536

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolarity I

This study exists to better understand the safety of a therapy or guided support program and how manageable it feels in practice. Researchers are trying to understand how people respond to a therapy or guided support program in practice and what may need to be adjusted.

DepressionOtherFrom 18 Years to 65 Years
Countries
Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Hungary, Italy, Poland, Serbia, Slovakia, South Africa, Spain, Ukraine, United States
Sponsor
Cephalon
Condition
Depression
CompletedNCT01567527

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

This study exists to see whether the medication OPC-14597 can make care clearer and more responsive. Researchers are trying to understand whether the medication OPC-14597 can better prevent setbacks and support longer-term stability.

BipolarityOtherFrom 18 Years to 65 Years
Countries
Canada, Japan, Poland, Romania, South Korea, Taiwan, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity
TerminatedNCT01928043

Adjunctive Curcumin for Symptomatic Adolescents With Bipolarity: Brain and Body Considerations

This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.

BipolarityOtherFrom 13 Years to 19 Years
Countries
Canada
Sponsor
Sunnybrook Health Sciences Centre
Condition
Bipolarity
CompletedNCT01396447

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Depression in bipolarity

This study exists to understand whether this type of care is both safe enough and useful enough to take further. For people living with Depression, that matters because care needs to work in daily life, not just in theory.

DepressionOtherFrom 18 Years to 65 Years
Countries
Bulgaria, Canada, Colombia, Russian Federation, Ukraine, United States
Sponsor
Forest Laboratories
Condition
Depression
CompletedNCT02593643

Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Depression in bipolarity.

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can better prevent setbacks and support longer-term stability.

DepressionOtherFrom 18 Years to 65 Years
Countries
Canada
Sponsor
Sunnybrook Health Sciences Centre
Condition
Depression
CompletedNCT01075295

Prevention of Weight Gain in Early Psychoses

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 14 Years to 45 Years
Countries
Canada
Sponsor
Centre for Addiction and Mental Health
Condition
Schizophrenia
CompletedNCT00139594

Open Label Extension Study of Licarbazepine in the Treatment of manic episodes of Bipolarity I

This study exists to understand how the medication Licarbazepine holds up over time after the earliest research stage. For people living with Bipolarity, that matters because care needs to work in daily life, not just in theory.

BipolarityOtherFrom 18 Years to 70 Years
Countries
Austria, Canada, Colombia, Czech Republic, Germany, Guatemala, Peru, Russian Federation, Slovakia, South Africa, Ukraine, United States, Venezuela
Sponsor
Novartis
Condition
Bipolarity
CompletedNCT02147379

Lurasidone and Cognition in Bipolarity I

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

BipolarityOtherFrom 19 Years to 65 Years
Countries
Canada
Sponsor
University of British Columbia
Condition
Bipolarity
CompletedNCT01403662

Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Depression in bipolarity

This study exists to understand how a therapy or guided support program holds up over time after the earliest research stage. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

DepressionOtherFrom 18 Years to 65 Years
Countries
Canada
Sponsor
University Health Network, Toronto
Condition
Depression
CompletedNCT01485640

Lurasidone Extended Use Study

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOther
Countries
Canada, Colombia, Czech Republic, France, India, Lithuania, Romania, Russian Federation, Serbia, Slovakia, South Africa, Ukraine
Sponsor
Sumitomo Pharma America, Inc.
Condition
Schizophrenia
CompletedNCT01828931

Lifestyle Intervention for Diabetes and Weight Management in Psychosis

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
Canada
Sponsor
Centre for Addiction and Mental Health
Condition
Schizophrenia
WithdrawnNCT02476331

A Trial of Cognitive Training in Euthymic Bipolarity

This study exists to compare options and see whether the medication Cognitive offers something meaningfully different. Researchers are trying to understand whether the medication Cognitive can improve attention, thinking, or day-to-day functioning.

BipolarityOtherFrom 18 Years to 65 Years
Countries
Canada
Sponsor
University of Calgary
Condition
Bipolarity
CompletedNCT02423824

Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists

This study exists to understand how a therapy or guided support program holds up over time after the earliest research stage. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

DepressionOtherFrom 18 Years to 45 Years
Countries
Canada
Sponsor
University Health Network, Toronto
Condition
Depression
CompletedNCT01072630

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolarity I

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand what a therapy or guided support program could change in day-to-day care and decision-making.

DepressionOtherFrom 18 Years to 65 Years
Countries
Argentina, Australia, Bulgaria, Canada, France, Poland, South Africa, Spain, Ukraine, United States
Sponsor
Cephalon
Condition
Depression
CompletedNCT00868959

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

This study exists to explore whether the medication Patients could improve care and understanding. For people living with Depression, that matters because care needs to work in daily life, not just in theory.

DepressionOtherFrom 18 Years to 75 Years
Countries
Canada, Colombia, Czech Republic, France, India, Japan, Lithuania, Peru, Poland, Romania, Russian Federation, Slovakia, South Africa, Ukraine, United States
Sponsor
Sumitomo Pharma America, Inc.
Condition
Depression
CompletedNCT01768000

The Family Cognitive Adaptation Training Manual: A Test of Effectiveness

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherOver 16 Years
Countries
Canada
Sponsor
Centre for Addiction and Mental Health
Condition
Schizophrenia